Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD ...

The label-free device uses a copper surface with p53 antigen to detect antibodies instantly via microwave signals.

A review of recent literature shows bioengineering is reshaping oncology, from synthetic biology to nanomedicine, but what's ...

Recent advancements in medical technology suggest that simple blood tests could significantly enhance early cancer detection.

The Hong Kong University of Science and Technology (HKUST) today launched SmartPath, a comprehensive artificial intelligence ...

For many Tennesseans, biomarker tests are not covered by insurance, which ultimately prevents them from receiving personalized testing and treatment.

Turku, Finland-based immunotherapy developer Faron tested its lead asset in combination with azacitidine. First and second-phase data resulted in an 85% objective response rate and a 45% complete ...

Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany, was host to the session Mini Oral session 2: GU tumours, renal & urothelial Dr. Tian Zhang ...

Dr. Simsek began by emphasizing that their group had previously shown that CD8+ T cells expressing PD-1 but lacking TIM-3 or LAG-3 are associated with improved clinical outcomes to anti–PD-1 ...